High Throughput Immunoassay for Flagellin

鞭毛蛋白的高通量免疫分析

• 批准号: 8516169
• 负责人: MARTIN D. CHAPMAN
• 金额: $ 18.43万
• 依托单位: INDOOR BIOTECHNOLOGIES
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-15 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8516169
• 关键词: Academia; Accounting; Adjuvant; Admission activity; Affect; Affinity; Allergens; Allergic; Allergic Disease; Animals; Antibodies; Asthma; Atopic Dermatitis; Bacteria; Bacterial Proteins; Biological Assay; Biological Markers; Biotechnology; Canis familiaris; Centers for Disease Control and Prevention (U.S.); Child; Childhood; Chronic Disease; Collaborations; Communicable Diseases; Complement; Detection; Development; Dictyoptera; Disease; Dose; Dust; Endotoxins; Environmental Exposure; Environmental Monitoring; Enzyme-Linked Immunosorbent Assay; Europe; Exclusion; Exposure to; Family; Farming environment; Felis catus; Flagella; Flagellin; Genetic; Goals; Government Agencies; Hay fever; High Pressure Liquid Chromatography; Home environment; Hospitalization; Hospitals; House Dust; Household; Housing; Human; Hypersensitivity; Immune response; Immunoassay; Immunoblotting; Immunology; Infectious Disease Immunology; Investigation; Ion Exchange; Life; Link; Low Prevalence; Manufacturer Name; Marketing; Measurement; Measures; Molds; Molecular Weight; Monoclonal Antibodies; Mus; National Institute of Environmental Health Sciences; Natural Immunity; Oryctolagus cuniculus; Patients; Performance; Pharmacologic Substance; Phase; Precipitation; Production; Proteins; Pseudomonas aeruginosa; Public Health; Reagent; Recombinants; Reproducibility; Research; Research Personnel; Risk Factors; Role; Sampling; Sensitivity and Specificity; Services; Site; Small Business Innovation Research Grant; Socioeconomic Status; Sodium Chloride; Standardization; Suspension substance; Suspensions; System; Techniques; Testing; Toll-Like Receptor 5; Ultrafiltration; Vaccines; air sampling; allergic response; base; commercialization; cooking; early childhood; economic cost; environmental allergen; mouse model; polyclonal antibody; protective effect; public health relevance; pyroglyphid; research study; respiratory; response; tool

DESCRIPTION (provided by applicant): Asthma is a serious public health problem in the US that affects one in ten schoolchildren and causes ~500,000 hospitalizations each year, with an estimated economic cost of $56 billion. Allergic sensitization to household allergens (dust mites, cat, dog, mouse, cockroach, molds) is a major risk factor for the development of asthma. Asthma in early childhood can also be influenced by exposure to bacterial products which may potentiate or have protective effects depending on the level of environmental exposure and genetic factors. Recent studies in a mouse model have shown that the bacterial protein, flagellin, promotes allergic sensitization to indoor allergens and that human patients with asthma have high levels of antibodies to flagellin. Household dust samples have been shown to contain flagellin. However, investigation of the association between exposure to flagellin and asthma requires a robust test to measure flagellin in environmental samples from homes and public buildings. The goal of this SBIR Phase I project is to develop a high throughput immunoassay for flagellin, capable of analyzing several hundred samples per week. The specific aims of the project are i) to purify flagellin from Pseudomonas aeruginosa; ii) to develop a monoclonal or polyclonal antibody based immunoassay which detects flagellin from most bacterial species; iii) to validate the assay performance to measure flagellin in dust samples of known allergen and endotoxin content. The strategy involves developing a multiplexed immunoassay which can be used to measure flagellin, allergens and molds simultaneously. This assay will be to assess the role of flagellin exposure in allergic disease. Commercial potential: Successful completion of this SBIR will result in valuable immunoassay product(s) that can be marketed by the applicant, Indoor Biotechnologies, to allergy/immunology researchers in academia, government agencies, pharmaceutical companies and vaccine manufacturers, worldwide. The research could generate several product lines that are complementary to the company's current products and which will enable the company to expand its product range in new markets.

描述（由申请人提供）：哮喘在美国是一个严重的公共卫生问题，影响十分之一的学童，每年导致约 50 万人住院，估计经济损失达 560 亿美元。对家庭过敏原（尘螨、猫、狗、老鼠、蟑螂、霉菌）的过敏是发生哮喘的主要危险因素。儿童早期的哮喘也可能受到接触细菌产物的影响，细菌产物可能会增强或具有保护作用，具体取决于环境暴露水平和遗传因素。最近对小鼠模型的研究表明，细菌蛋白鞭毛蛋白会促进对室内过敏原的过敏，并且人类哮喘患者具有高水平的鞭毛蛋白抗体。家庭灰尘样本已被证明含有鞭毛蛋白。然而，调查暴露于鞭毛蛋白和哮喘之间的关联需要进行强有力的测试来测量家庭和公共建筑环境样本中的鞭毛蛋白。 SBIR 第一阶段项目的目标是开发一种高通量鞭毛蛋白免疫测定方法，每周能够分析数百个样本。该项目的具体目标是 i) 从铜绿假单胞菌中纯化鞭毛蛋白； ii) 开发基于单克隆或多克隆抗体的免疫测定法，检测大多数细菌物种的鞭毛蛋白； iii) 验证测量已知过敏原和内毒素含量的灰尘样品中鞭毛蛋白的测定性能。该策略涉及开发一种多重免疫测定法，可用于同时测量鞭毛蛋白、过敏原和霉菌。该测定将评估鞭毛蛋白暴露在过敏性疾病中的作用。商业潜力：成功完成此项目 SBIR 将产生有价值的免疫测定产品，可由申请人 Indoor Biotechnologies 向全球学术界、政府机构、制药公司和疫苗制造商的过敏/免疫学研究人员销售。该研究可能会产生多个产品线，与公司当前的产品形成互补，并使公司能够在新市场上扩大其产品范围。